BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27734584)

  • 1. Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation.
    Takeuchi M; Tanoshima R; Miyagawa N; Sarashina T; Kato H; Kajiwara R; Ito S; Goto H
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27734584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
    Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment.
    Hayakawa M; Yamamoto H; Honma T; Mukai N; Higashiyama A; Sugano M; Kubota N; Uegaki S; Sawamura A; Gando S
    Shock; 2012 Jun; 37(6):569-73. PubMed ID: 22552020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing Surveillance of Recombinant Human Soluble Thrombomodulin (Thrombomodulin α) in Pediatric Patients With Disseminated Intravascular Coagulation.
    Shirahata A; Mimuro J; Takahashi H; Tsuji H; Kitajima I; Matsushita T; Eguchi Y; Kitamura N; Honda G; Sakata Y
    Clin Appl Thromb Hemost; 2014 Jul; 20(5):465-72. PubMed ID: 24563247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
    Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
    Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of thrombomodulin alfa to support dosing rationale in patients with renal impairment.
    Mouksassi MS; Marier JF; Bax L; Osawa Y; Tsuruta K
    Clin Pharmacol Drug Dev; 2015; 4(3):210-7. PubMed ID: 27140801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects.
    Tsuruta K; Yamada Y; Serada M; Tanigawara Y
    J Clin Pharmacol; 2011 Sep; 51(9):1276-85. PubMed ID: 21098690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early thrombomodulin-α administration outcome for acute disseminated intravascular coagulopathy in gastrointestinal surgery.
    Konishi H; Okamoto K; Shoda K; Arita T; Kosuga T; Morimura R; Komatsu S; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Otsuji E
    World J Gastroenterol; 2017 Feb; 23(5):891-898. PubMed ID: 28223734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.
    Nakano K; Sugiyama K; Satoh H; Arifuku H; Fujimatsu T; Yoshida N; Watanabe H; Tokita S; Wakayama T; Tatewaki M; Souma R; Masuda H; Koyama K; Hirata H; Fukushima Y
    Intern Med; 2017; 56(14):1799-1806. PubMed ID: 28717074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
    Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of the safety and efficacy of recombinant human soluble thrombomodulin in patients with obstetrical disseminated intravascular coagulation.
    Kobayashi T; Kajiki M; Nihashi K; Honda G
    Thromb Res; 2017 Nov; 159():109-115. PubMed ID: 29153952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
    Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
    Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
    Aikawa N; Shimazaki S; Yamamoto Y; Saito H; Maruyama I; Ohno R; Hirayama A; Aoki Y; Aoki N
    Shock; 2011 Apr; 35(4):349-54. PubMed ID: 21068698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction.
    Hayakawa M; Kushimoto S; Watanabe E; Goto K; Suzuki Y; Kotani T; Kiguchi T; Yatabe T; Tagawa J; Komatsu F; Gando S
    Thromb Haemost; 2017 May; 117(5):851-859. PubMed ID: 28229162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.
    Imaura M; Tsumori M; Nagase S; Omura K; Takahashi H; Hatoyama-Tanaka S; Katagiri F; Takayanagi R; Kanno H; Yamada Y
    Shock; 2020 Jul; 54(1):50-55. PubMed ID: 31764622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation.
    Shirahata A; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kajiki M; Honda G; Sakata Y
    Eur J Pediatr; 2014 Mar; 173(3):303-11. PubMed ID: 24005342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombomodulin alfa prevents the decrease in platelet aggregation in rat models of disseminated intravascular coagulation.
    Kimpara N; Tawara S; Kawasaki K
    Thromb Res; 2019 Jul; 179():73-80. PubMed ID: 31096113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution--an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases.
    Kawano N; Tasaki A; Kuriyama T; Tahara Y; Yoshida S; Ono N; Himeji D; Yamashita K; Shibata Y; Goto T; Inoue T; Yokota-Ikeda N; Uezono S; Yuge A; Nishiguchi T; Kinjo T; Ogura Y; Beppu K; Ueda Y; Kinoshita M; Moritake H; Shimoda K; Ochiai H; Ueda A
    Intern Med; 2014; 53(3):205-13. PubMed ID: 24492688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin.
    Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Thromb Res; 2019 Jan; 173():57-64. PubMed ID: 30472436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan: An Epidemiological Study Based on a National Administrative Database.
    Murata A; Okamoto K; Mayumi T; Muramatsu K; Matsuda S
    Clin Appl Thromb Hemost; 2016 Jan; 22(1):21-7. PubMed ID: 25736054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.